X4 Pharmaceuticals Had $102.8M In Cash, Cash Equivalents, Restricted Cash, And Marketable Securities As Of December 31, 2024. Pro-forma For €28.5M Received From Norgine In January 2025 And The Expected Financial Impact Of The Strategic Restructuring Announced In February 2025, The Company Believes It Has Sufficient Funds To Support Operations Into 1H Of 2026

Benzinga

2025/03/25

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2522046825"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2522046825\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2522046825?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-25 18:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2522046825","market":"us","top_or_hot":-1,"title":"X4 Pharmaceuticals Had $102.8M In Cash, Cash Equivalents, Restricted Cash, And Marketable Securities As Of December 31, 2024. Pro-forma For €28.5M Received From Norgine In January 2025 And The Expected Financial Impact Of The Strategic Restructuring Announced In February 2025, The Company Believes It Has Sufficient Funds To Support Operations Into 1H Of 2026","media":"Benzinga","content":"<html><body><p>X4 Pharmaceuticals Had $102.8M In Cash, Cash Equivalents, Restricted Cash, And Marketable Securities As Of December 31, 2024. Pro-forma For €28.5M Received From Norgine In January 2025 And The Expected Financial Impact Of The Strategic Restructuring Announced In February 2025, The Company Believes It Has Sufficient Funds To Support Operations Into 1H Of 2026</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>X4 Pharmaceuticals Had $102.8M In Cash, Cash Equivalents, Restricted Cash, And Marketable Securities As Of December 31, 2024. Pro-forma For €28.5M Received From Norgine In January 2025 And The Expected Financial Impact Of The Strategic Restructuring Announced In February 2025, The Company Believes It Has Sufficient Funds To Support Operations Into 1H Of 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nX4 Pharmaceuticals Had $102.8M In Cash, Cash Equivalents, Restricted Cash, And Marketable Securities As Of December 31, 2024. Pro-forma For €28.5M Received From Norgine In January 2025 And The Expected Financial Impact Of The Strategic Restructuring Announced In February 2025, The Company Believes It Has Sufficient Funds To Support Operations Into 1H Of 2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2025-03-25 18:04</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>X4 Pharmaceuticals Had $102.8M In Cash, Cash Equivalents, Restricted Cash, And Marketable Securities As Of December 31, 2024. Pro-forma For €28.5M Received From Norgine In January 2025 And The Expected Financial Impact Of The Strategic Restructuring Announced In February 2025, The Company Believes It Has Sufficient Funds To Support Operations Into 1H Of 2026</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.benzinga.com/general/biotech/25/03/44469846/x4-pharmaceuticals-had-102-8m-in-cash-cash-equivalents-restricted-cash-and-marketable-securities-","article_id":"2522046825","we_media_id":"1052270027","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2522046825","pubTimestamp":1742897085,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Benzinga","introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"summary":"X4 Pharmaceuticals Had $102.8M In Cash, Cash Equivalents, Restricted Cash, And Marketable Securities As Of December 31, 2024. Pro-forma For 28.5M Received From Norgine In January 2025 And The Expected Financial Impact Of The Strategic Restructuring Announced In February 2025, The Company Believes It Has Sufficient Funds To Support Operations Into 1H Of 2026","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","XFOR":"X4制药"},"translate_title":"截至2024年12月31日，X4 Pharmaceuticals拥有1.028亿美元的现金、现金等价物、限制性现金和有价证券。预计2025年1月从Norgine收到的2850万欧元以及2025年2月宣布的战略重组的预期财务影响，公司相信其有足够的资金支持2026年上半年的运营","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XFOR":0.9},"content_text":"X4 Pharmaceuticals Had $102.8M In Cash, Cash Equivalents, Restricted Cash, And Marketable Securities As Of December 31, 2024. Pro-forma For €28.5M Received From Norgine In January 2025 And The Expected Financial Impact Of The Strategic Restructuring Announced In February 2025, The Company Believes It Has Sufficient Funds To Support Operations Into 1H Of 2026","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}